Why Merck Is Poised to Outperform

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, drug behemoth Merck (NYSE: MRK  ) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Merck and see what CAPS investors are saying about the stock right now.

Merck facts

Headquarters (founded)

Whitehouse Station, N.J. (1891)

Market Cap

$132.4 billion

Industry

Pharmaceuticals

Trailing-12-Month Revenue

$47.8 billion

Management

Chairman/CEO Kenneth Frazier
CFO Peter Kellogg

Return on Equity (average, past 3 years)

12.9%

Cash/Debt

$18.1 billion / $19.6 billion

Dividend Yield

4%

Competitors

GlaxoSmithKline (NYSE: GSK  )
Novartis (NYSE: NVS  )
Pfizer (NYSE: PFE  )

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 93% of the 2,883 members who have rated Merck believe the stock will outperform the S&P 500 going forward.

Earlier today, one of those Fools, TMFCane, succinctly summed up the Merck bull case for our community:

Januvia and Janumet are poised to explode with the diabetes market. Suvorexant and odanacatib both look good, and keeping all its divisions together (rather than spinning them off a la Abbott and Pfizer) should allow Merck to capitalize on growth segments. This company's done well in compensating for Singulair's loss.

If you want market-thumping returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. 

For nearly 100 years, Merck's cutting-edge research has led to a number of medical breakthroughs. Today, however, this pharma stalwart is staring down a steep patent cliff and facing generic competition for its top-selling drug. Will Merck crumble under its own weight, or will it continue to pay dividends to investors for another century? To find out if this pharma giant has the stamina to keep its Bunsen burners alight, grab your copy of our brand new premium research report today. Our senior biotech analyst Brian Orelli, Ph.D., walks you through both the opportunities and threats facing Merck, and the report comes with a full 12 months of updates. Claim your copy now by clicking here.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2157964, ~/Articles/ArticleHandler.aspx, 7/23/2014 5:01:21 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement